Inventor

KING DAVID JOHN

GB13 patents

⚠️ This page may combine multiple inventors who share the name “KING DAVID JOHN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

CELLTECH LTD

2 patents

US6307026B1Oct 23, 2001

Humanized antibodies directed against A33 antigen

CELLTECH LTD83 citations97

US5864019AJan 26, 1999

Multivalent antigen-binding proteins

CELLTECH LTD136 citations96

UCB PHARMA SA

2 patents

US7402662B2Jul 22, 2008

Antibody molecules specific to human tumor necrosis factor alpha

UCB PHARMA SA12 citations89

US7977464B2Jul 12, 2011

Antibody molecules specific to human tumour necrosis factor alpha

UCB PHARMA SA3 citations61

CELLTECH R&D LTD

1 patent

US6511663B1Jan 28, 2003

Tri- and tetra-valent monospecific antigen-binding proteins

CELLTECH R&D LTD172 citations97

MEDAREX INC

1 patent

US8034959B2Oct 11, 2011

Methods of treating cancer with an antibody-drug conjugate

MEDAREX INC37 citations95

CELLTECH CHIROSCIENCE LTD

1 patent

US7012135B2Mar 14, 2006

Biological products

CELLTECH CHIROSCIENCE LTD63 citations94

TERRET JONATHAN ALEXANDER

1 patent

US8124738B2Feb 28, 2012

Human monoclonal antibodies to CD70

TERRET JONATHAN ALEXANDER102 citations93

RAO-NAIK CHETANA

1 patent

US8097703B2Jan 17, 2012

CD19 antibodies and their uses

RAO-NAIK CHETANA71 citations92

KING DAVID JOHN

1 patent

US8481683B2Jul 9, 2013

Human antibodies that bind CD22 and uses thereof

KING DAVID JOHN31 citations87

SQUIBB & SONS LLC

1 patent

US9499632B2Nov 22, 2016

Human antibodies that bind CD22 and uses thereof

SQUIBB & SONS LLC8 citations82

UCB CELLTECH

1 patent

US7186820B2Mar 6, 2007

Production of humanised antibodies to TNFα

UCB CELLTECH10 citations79

CHAPMAN ANDREW PAUL

1 patent

US8067005B1Nov 29, 2011

Divalent antibody fragments

CHAPMAN ANDREW PAUL11 citations78